Alzamend Neuro reported its Q2 2025 financial results, highlighting improved financial position. Net cash from financing activities reached $8.3M for the six months ended October 31, 2024. Stockholder equity rose to $3.8M, with cash increasing to $4.1M, while total liabilities decreased to $1.3M.The company entered agreements for up to $25M in preferred stock and warrants, and an at-the-market option for up to $6.5M in common stock sales. These moves strengthened Alzamend's balance sheet, regained Nasdaq compliance, and prepared for five clinical trials in 2025.Alzamend's lead candidate, AL001, a novel lithium formulation, is set for five Phase II trials in 2025 for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. ALZN002, an immunotherapy for Alzheimer's, plans to resume its Phase I/IIA trial in 2025. The company remains committed to developing treatments for over 43 million Americans affected by these conditions.

Alzamend Neuro reported its Q2 2025 financial results, highlighting improved financial position. Net cash from financing activities reached $8.3M for the six months ended October 31, 2024. Stockholder equity rose to $3.8M, with cash increasing to $4.1M, while total liabilities decreased to $1.3M.The company entered agreements for up to $25M in preferred stock and warrants, and an at-the-market option for up to $6.5M in common stock sales. These moves strengthened Alzamend's balance sheet, regained Nasdaq compliance, and prepared for five clinical trials in 2025.Alzamend's lead candidate, AL001, a novel lithium formulation, is set for five Phase II trials in 2025 for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. ALZN002, an immunotherapy for Alzheimer's, plans to resume its Phase I/IIA trial in 2025. The company remains committed to developing treatments for over 43 million Americans affected by these conditions.